STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #243 by analyst upside · 2026-08-13
OTLK
Outlook Therapeutics, Inc.
Healthcare · Market Cap $206M · P/E 0x
ANALYST PRICE TARGET
+390.9%
implied upside to consensus target
Current Price $1.1
Consensus Target $5.4
Bull Target $10.0
Bear Target $1.6
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
1
Sell
0
52-Week Low $0.16
52-Week High $3.39
YTD Return +66.7%
FUNDAMENTALS
Market Cap $206M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.10
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.16
52-Week High $3.39
Current Price $1.1
Bear Target $1.6
Bull Target $10.0
● Now $1.1 ● Target $5.4
TRADING DATA
Avg Volume 22.3M
YTD Return +66.7%
Analyst Count 4
Consensus Buy
Upside to Target +390.9%
Last Updated 2026-08-13

ANALYST SUMMARY

Outlook Therapeutics, Inc. (OTLK) is currently trading at $1.1 with a Wall Street consensus price target of $5.4, implying potential upside of 390.9% over the next 12 months. 4 analysts currently cover OTLK, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $1.6.

OTLK operates in the Healthcare sector with a market capitalisation of $206M. The stock is up 66.7% year-to-date and is currently trading near the lower end of its 52-week range of $0.16 – $3.39.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OTLK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ascendiant Capital - Reiterated
Buy → Buy 2026-06-11 Building track record
BTIG ↓ Downgrade
Buy → Neutral 2026-05-18 38% win rate (8 calls)
Ascendiant Capital - Reiterated
Buy → Buy 2026-03-11 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2026-02-18 31% win rate (48 calls)
Chardan Capital - Reiterated
Neutral → Neutral 2026-02-18 33% win rate (6 calls)
Chardan Capital - Reiterated
Neutral → Neutral 2026-01-05 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Neutral → Neutral 2026-01-02 31% win rate (48 calls)
Ascendiant Capital - Reiterated
Buy → Buy 2025-12-22 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →